Cheruvu Pavan 4
4 · Axovant Gene Therapies Ltd. · Filed Jul 10, 2020
Insider Transaction Report
Form 4
Cheruvu Pavan
Chief Executive Officer
Transactions
- Purchase
Common Shares
2020-07-08$2.74/sh+37,500$102,638→ 57,836 total
Footnotes (2)
- [F1]The purchases reported in this Form 4 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the sales of shares by the reporting person at $3.09 per share on June 11, 2020. The reporting person has paid to the Issuer the $3,616.37 loss avoided by the reporting person in connection with the short-swing transaction.
- [F2]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.70 to $2.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchase at each separate price within the range set forth in this footnote.